25 February 2021

Takeda announced that the first participant has been dosed with Novavax’s Covid-19 vaccine candidate (TAK-019) in Japan in a Phase I/II immunogenicity and safety study. Earlier this month, Takeda completed the enrolment of Moderna’s Covid-19 vaccine candidate (TAK-919) in a Phase I/II immunogenicity and safety study in the country. Takeda will manufacture Novavax’s recombinant vaccine and distribute Moderna’s mRNA vaccine with the support of the Japanese government.

The Egyptian Drug Authority has approved the Russian Direct Investment Fund‘s f its Sputnik V vaccine. Egypt is the 35th country in the world to have approved the Covid-19 Sputnik V vaccine for emergency use.

CVS Health added Alabama, Arizona, Louisiana, Florida, Ohio, and Pennsylvania to its list of states where some CVS pharmacy locations will offer Covid-19 vaccinations to eligible populations through the Federal Retail Pharmacy Programme. This follows on from the successful rollout in 11 US states on 12 February 2021.

Moderna is making new investments to boost capacity at its own and partner’s manufacturing facilities in order to increase its global 2022 capacity to about 1.4 billion Covid-19 vaccine doses. The investments will support the increase in production of the Moderna COVID-19 vaccine and potential vaccine boosters needed to address emerging SARS-CoV-2 variants.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.